SCHEMBL585370

SCHEMBL585370

CCCCCCCCCCCCN(CCCC)C(=O)CCC(=O)NCCCC

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.56
DNM1 Q05193 2/20 0.55
NAAA Q02083 1/20 0.53
FAAH O00519 4/20 0.50
EPHX1 P07099 4/20 0.46
KDM4A O75164 1/20 0.46
HIF1A Q16665 1/20 0.46
TET2 Q6N021 1/20 0.46
DOHH Q9BU89 1/20 0.46
CNR1 P21554 1/20 0.45
LPAR1 Q92633 1/20 0.43
EPHX2 P34913 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26037662 0.98 CASP2 (0.58) CASP2DNM1NAAAFAAHEPHX1
SCHEMBL7897141 0.95 CASP2 (0.62) CASP2DNM1NAAAFAAHEPHX1
SCHEMBL30890794 0.93 DNM1 (0.56) CASP2DNM1NAAAFAAHEPHX1
SCHEMBL14880032 0.89 NAAA (0.61) CASP2DNM1NAAAFAAHEPHX1
SCHEMBL6866377 0.88 DNM1 (0.50) CASP2DNM1NAAAFAAHKDM4A
SCHEMBL6860236 0.88 DNM1 (0.50) CASP2DNM1NAAAFAAHKDM4A
SCHEMBL27347939 0.87 DNM1 (0.64) CASP2DNM1NAAAFAAHEPHX1
SCHEMBL1258600 0.87 DNM1 (0.50) CASP2DNM1NAAAFAAHEPHX1
SCHEMBL15397314 0.87 FAAH (0.61) CASP2DNM1NAAAFAAHKDM4A
SCHEMBL16900384 0.86 CNR1 (0.68) CNR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12343411-B2 Compositions and methods for treating keratinous substrates L'OREAL (FR) 2025-07-01 US disclosed
WO-2020242787-A1 COMPOSITIONS AND METHODS FOR TREATING KERATINOUS SUBSTRATES LI DONGCUI (US) 2020-12-03 WO disclosed
US-20200375854-A1 COMPOSITIONS AND METHODS FOR TREATING KERATINOUS SUBSTRATES L'OREAL (FR) 2020-12-03 US disclosed
EP-1718269-B1 MAKE-UP COMPOSITION PROCTER & GAMBLE (US) 2014-12-17 EP disclosed
US-8597622-B2 Deodorant cosmetic composition comprising a combination of a lipophilic salicylic acid derivative and an antiperspirant aluminium salt L'OREAL (FR) 2013-12-03 US disclosed
US-8563754-B2 Compounds, compositions and methods for preventing skin darkening NEW YORK UNIVERSITY (US) 2013-10-22 US disclosed
WO-2012072409-A2 PROCESS FOR TREATING BODY ODOUR COMBINING A TOPICAL DEODORANT PRODUCT WITH AN ORAL PERFUME; DEODORIZING KIT L'OREAL (FR) 2012-06-07 WO disclosed
EP-1791603-B1 COSMETIC COMPOSITION COMPRISING AS ANTIPERSPIRANT AGENT A FLOCCULATING WATER-SOLUBLE POLYMER; PROCESS FOR TREATING PERSPIRATION OREAL (FR) 2012-05-09 EP disclosed
EP-1011629-B1 CLEANSING AND CONDITIONING PRODUCTS FOR SKIN OR HAIR WITH IMPROVED DEPOSITION OF CONDITIONING INGREDIENTS PROCTER & GAMBLE (US) 2012-03-21 EP disclosed
EP-1416905-B1 Sunscreen composition PROCTER & GAMBLE (US) 2012-02-15 EP disclosed
US-5840287-A AMIDE COMPOUND WITH GELLING AGENT AND ACTIVE MATERIAL PROCTER & GAMBLE COMPANY (US) 1998-11-24 US disclosed
WO-1998027951-A2 ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS SUBSTANTIALLY FREE OF SELECT POLAR SOLVENTS THE PROCTER & GAMBLE COMPANY (US) 1998-07-02 WO disclosed
WO-1998027950-A1 ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1998-07-02 WO disclosed
WO-1998027949-A1 ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1998-07-02 WO disclosed
WO-1998027955-A1 ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1998-07-02 WO disclosed
WO-1998027952-A1 METHODS OF MAKING LOW RESIDUE ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1998-07-02 WO disclosed
WO-1998027939-A2 ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS CONTAINING SELECT NUCLEATING AGENTS THE PROCTER & GAMBLE COMPANY (US) 1998-07-02 WO disclosed
WO-1998027954-A1 ANTIPERSPIRANT COMPOSITIONS CONTAINING GELLANTS IN THE FORM OF ALKYL AMIDES OF DI- AND TRI-CARBOXYLIC ACIDS THE PROCTER & GAMBLE COMPANY (US) 1998-07-02 WO disclosed
US-5744130-A COMPRISING ACTIVE MATERIAL, NONPOLYMERIC GELLANT, ANHYDROUS LIQUID CARRIER; LOW RESIDUE THE PROCTER & GAMBLE COMPANY (US) 1998-04-28 US disclosed
WO-1998016196-A1 COMPOSITIONS AND METHODS FOR IMPROVING THE PERFORMANCE OF LONG-WEARING COSMETIC PRODUCTS THE PROCTER & GAMBLE COMPANY (US) 1998-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12343411-B2 Compositions and methods for treating keratinous substrates KRT18, GK, LIPA CASP2 3094/4885DNM1 2707/4885NAAA 2261/4885
US-20200375854-A1 COMPOSITIONS AND METHODS FOR TREATING KERATINOUS SUBSTRATES KRT18, GK, LIPA CASP2 3094/4885DNM1 2707/4885NAAA 2261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.